BioClin Therapeutics

OverviewSuggest Edit

BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. The company's lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. 
Currently, two proof-of-concept Phase 1b/2 studies with B-701 in 2nd line metastatic bladder cancer are being launched.
In addition to exploring the efficacy of B-701 as a treatment for FGFR3-driven cancer, BioClin is testing the ability of B-701 to treat an orphan condition called achondroplasia, which is the most common form of human disproportionate dwarfism. In achondroplasia, long bone growth is stunted due to the enhanced activity of FGFR3; thus blocking activation of this receptor has the potential to restore long bone growth.

TypePrivate
Founded2010
HQSan Ramon, US
Websitebioclintherapeutics.com

Locations

BioClin Therapeutics is headquartered in
San Ramon, United States

Location Map

Latest Updates

Employees (est.) (Oct 2019)25

Key People/Management at BioClin Therapeutics

Stephen Lau

Stephen Lau

CEO

BioClin Therapeutics Office Locations

BioClin Therapeutics has an office in San Ramon
San Ramon, US (HQ)
130 Market Pl
Show all (1)

BioClin Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2010

BioClin Therapeutics total Funding

$69 m

BioClin Therapeutics latest funding size

$30 m

Time since last funding

3 years ago

BioClin Therapeutics investors

BioClin Therapeutics's latest funding round in March 2017 was reported to be $30 m. In total, BioClin Therapeutics has raised $69 m
Show all financial metrics

BioClin Therapeutics Online and Social Media Presence

Embed Graph

BioClin Therapeutics Frequently Asked Questions

  • When was BioClin Therapeutics founded?

    BioClin Therapeutics was founded in 2010.

  • Who are BioClin Therapeutics key executives?

    BioClin Therapeutics's key executives are Stephen Lau.

  • How many employees does BioClin Therapeutics have?

    BioClin Therapeutics has 25 employees.

  • Who are BioClin Therapeutics competitors?

    Competitors of BioClin Therapeutics include Karyopharm Therapeutics, Calithera Biosciences and Clovis Oncology.

  • Where is BioClin Therapeutics headquarters?

    BioClin Therapeutics headquarters is located at 130 Market Pl, San Ramon.

  • Where are BioClin Therapeutics offices?

    BioClin Therapeutics has an office in San Ramon.

  • How many offices does BioClin Therapeutics have?

    BioClin Therapeutics has 1 office.